lisdexamfetamine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 42 Diseases   12 Trials   12 Trials   1286 News 


12345678910111213...1415»
  • ||||||||||  methylphenidate tablet / Generic mfg., lisdexamfetamine / Generic mfg.
    Journal:  The need for speed? Exploring the risks and benefits of pharmacological treatment for adult ADHD in prisons. (Pubmed Central) -  Dec 16, 2024   
    To evaluate the impact of pharmacological ADHD treatment for adults who are or have been in prison, a narrative literature review was completed and seven international studies were identified. Further research into the use of stimulant medication in prisons, particularly within the Australian context, is recommended.
  • ||||||||||  centanafadine SR (EB-1020) / Otsuka
    Journal:  Treatment Preferences of Physicians Treating Adult Patients with Attention-Deficit/Hyperactivity Disorder (Pubmed Central) -  Nov 18, 2024   
    Efficacy was the most important single attribute for physicians treating adult patients with ADHD in both the US and Canada; however, the risks of AEs taken together had greater relative importance than efficacy alone among US but not Canadian physicians. These findings highlight potential discrepancies in physician and patient preferences based on existing evidence and underscore the importance of shared decision-making, which may in turn increase patients' treatment satisfaction.
  • ||||||||||  lisdexamfetamine / Generic mfg., dextroamphetamine immediate release / Generic mfg.
    Review, Journal:  Comparative pharmacology and abuse potential of oral dexamphetamine and lisdexamfetamine-A literature review. (Pubmed Central) -  Nov 13, 2024   
    Lisdexamfetamine improved both subjective and objective measures of attention and working memory and could offer women experiencing cognitive difficulties post-risk-reducing salpingo-oophorectomy an alternative therapeutic option. The available evidence from pharmacodynamic, pharmacokinetic and abuse liability studies suggests a comparable potential for oral abuse of dexamphetamine and LDX.
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Trial completion date, Trial primary completion date:  Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment (clinicaltrials.gov) -  Oct 31, 2024   
    P3,  N=80, Active, not recruiting, 
    The available evidence from pharmacodynamic, pharmacokinetic and abuse liability studies suggests a comparable potential for oral abuse of dexamphetamine and LDX. Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Dec 2024
  • ||||||||||  lisdexamfetamine / Generic mfg., fluoxetine / Generic mfg.
    Journal:  Binge, Purge, and Wander: Navigating Bulimia and Attention Deficit Hyperactivity Disorder (ADHD). (Pubmed Central) -  Oct 11, 2024   
    Given the presence of symptoms suggestive of attention deficit hyperactivity disorder (ADHD), a one-month trial of lisdexamfetamine (LDX) was initiated...The significant improvement observed following the introduction of psychostimulants supports the hypothesis that untreated ADHD may contribute to the exacerbation of BN symptoms. Further research is essential to clarify the underlying mechanisms and establish a solid scientific basis for future clinical interventions and therapeutic strategies.
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Trial completion, Surgery, Bariatric surgery:  Bariatric Surgery and Pharmacokinetics of Lisdexamphetamine (clinicaltrials.gov) -  Oct 8, 2024   
    P=N/A,  N=12, Completed, 
    Further research is essential to clarify the underlying mechanisms and establish a solid scientific basis for future clinical interventions and therapeutic strategies. Recruiting --> Completed
  • ||||||||||  methylphenidate tablet / Generic mfg., lisdexamfetamine / Generic mfg., amphetamine / Generic mfg.
    Journal:  Recreational Cannabis Legalization: No Contribution to Rising Prescription Stimulants in the USA. (Pubmed Central) -  Sep 3, 2024   
    RC legalization did not contribute to a more pronounced rise in Schedule II stimulant distribution in states. Future studies could explore the impact of illicit cannabis use on stimulant rates and the impact of cannabis sales on distribution rates of non-stimulant ADHD pharmacotherapies and ADHD diagnoses.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
    Review, Journal:  Anti-obesity Drugs for the Treatment of Binge Eating Disorder: Opportunities and Challenges. (Pubmed Central) -  Aug 16, 2024   
    Findings from ongoing clinical trials are likely to provide further insight into the possible role of anti-obesity drugs for treating BED. Since these agents can hold the potential to be misused potentiating dietary restriction and pathological weight loss, it is crucial to promote responsible prescribing practices.
  • ||||||||||  Qelbree (viloxazine) / Supernus Pharma, Knight Therap
    Journal:  Treatment Preferences of Adult Patients with Attention-Deficit/Hyperactivity Disorder - A Discrete Choice Experiment. (Pubmed Central) -  Aug 12, 2024   
    Overall preferences for treatment profiles approximating centanafadine, lisdexamfetamine, atomoxetine, and viloxazine were estimated using adjusted total utilities...Accordingly, a profile resembling that of centanafadine would be preferred by an average patient compared to key competitors due to its favorable safety profile. These findings may help improve treatment decision-making, enhance treatment satisfaction, and foster adherence.
  • ||||||||||  Review, Journal:  Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases. (Pubmed Central) -  Aug 10, 2024   
    It is currently unclear whether the novel and promising glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide 1 (GLP-1) receptor agonists like tirzepatide and retatrutide help with BED and its comorbidities. However, these compounds have been reported to reduce binge eating in individuals with obesity or overweight.
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Journal:  N-Functionalization of 1,2-Azaborines. (Pubmed Central) -  Jul 15, 2024   
    General protocols for the N-functionalization of 1,2-azaborines with C(sp3), C(sp2), or C(sp) electrophiles are described. The syntheses of a new parental BN isostere of trans-stilbene and a BN isostere of a lisdexamfetamine derivative were accomplished with the developed methodology.
  • ||||||||||  Review, Journal:  Attention-Deficit / Hyperactivity Disorder in pregnancy and the postpartum period. (Pubmed Central) -  Jun 23, 2024   
    Specifically, providers should work collaboratively with patients and their support networks to balance the risks of perinatal ADHD medication with the risks of inadequately treated ADHD in pregnancy. The risks and impacts of ADHD in pregnancy can be successfully managed through preconception counselling and appropriate perinatal planning, management, and support.
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Trial completion:  FOCUS ADHD Mobile Health App for Adult ADHD Patients (clinicaltrials.gov) -  May 14, 2024   
    P=N/A,  N=73, Completed, 
    NCT03605680, NCT03605836, NCT00334880, NCT00190736, and NCT04016779. Recruiting --> Completed
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment (clinicaltrials.gov) -  May 7, 2024   
    P3,  N=141, Completed, 
    What we have observed in this study is noteworthy but requires further investigation, particularly in people who use LDX over a longer period of time. Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Sep 2023 | Trial primary completion date: Jul 2024 --> Sep 2023
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Journal:  Switch to Lisdexamfetamine in the Treatment of Attention-Deficit Disorder at a Psychiatric Outpatient Clinic for School-Aged Children: A Danish Cohort Study. (Pubmed Central) -  Apr 16, 2024   
    Objectives: This study aimed to examine switch from first-line methylphenidate (MPH) to lisdexamfetamine (LDX) in school-aged children with attention-deficit/hyperactivity disorder (ADHD)...The study included 394 children switching from MPH to LDX as either second-line or third-line treatment (atomoxetine [ATX] as second-line treatment) during the study period from April 1, 2013, to November 5, 2019...Similarly to MPH and ATX, the most frequent reasons for LDX discontinuation were AEs (74.4%) and lack of efficiency (34.7%). Implications: The findings support LDX as an important option in the personalized treatment of children with ADHD and may support prescribers in the clinical decision-making on switching medication.
  • ||||||||||  Journal, HEOR:  Attention-Deficit/Hyperactivity Disorder Medications and Work Disability and Mental Health Outcomes. (Pubmed Central) -  Mar 24, 2024   
    No associations were found for modafinil, atomoxetine, clonidine, and guanfacine...The results regarding work disability were significant only for the use of atomoxetine (aHR, 0.89; 95% CI, 0.82-0.97), especially among adolescents and young adults aged 16 to 29 years, (aHR, 0.82; 95% CI, 0.73-0.92). In this nationwide cohort study of adolescents and adults with ADHD, the use of ADHD medication was associated with fewer hospitalizations for both psychiatric and nonpsychiatric morbidity and lower suicidal behavior.
  • ||||||||||  A mysterious case of Acute interstitial Nephritis () -  Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_485;    
    It is important to remark that in some patients with biopsy proven AIN and in whom clinical and pathological findings are suggestive of drug-induced form, the offending drug cannot be identified despite meticulous investigations. AIN presents with many diagnostic challenges as the symptoms, lab and urine findings are neither sensitive nor specific.
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Preclinical, Journal:  Assessment of lisdexamfetamine on executive function in rats: A translational cognitive research. (Pubmed Central) -  Feb 26, 2024   
    Taken together, due to its certain pharmacokinetic and catecholamine releasing profiles, lisdexamfetamine produced better pharmacological action to improving executive function. Our finding provided valuable evidence on the ideal pharmacokinetic and neurochemical characteristics of amphetamine-type psychostimulants in cognition enhancement.
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Preclinical, Journal:  Can exposure to lisdexamfetamine dimesylate from juvenile period to peripubertal compromise male reproductive parameters in adult rats? (Pubmed Central) -  Feb 21, 2024   
    In adulthood, there was an increase in immobile sperm, reduced sperm count, morphometric changes in the testis, and altered oxidative parameters, without compromising male sexual behavior and fertility. These findings showed that LDX-treatment during the juvenile and peripubertal periods induced immediate systemic toxicity and adversely influenced reproductive function in adult life, indicating that caution is necessary when prescribing this drug during the peripubertal phase.
  • ||||||||||  A Rare Case of Bilateral Diaphragmatic Dysfunction in Beh (San Diego Convention Center, Area H (Hall H, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_6719;    
    These findings showed that LDX-treatment during the juvenile and peripubertal periods induced immediate systemic toxicity and adversely influenced reproductive function in adult life, indicating that caution is necessary when prescribing this drug during the peripubertal phase. His medications included methylphenidate, lisdexamfetamine, warfarin and pantoprazole...He was started on bilevel spontaneous timed therapy for management of diaphragmatic weakness, and colchicine 0...While neurologic involvement of Beh
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism (clinicaltrials.gov) -  Feb 12, 2024   
    P4,  N=48, Completed, 
    His medications included methylphenidate, lisdexamfetamine, warfarin and pantoprazole...He was started on bilevel spontaneous timed therapy for management of diaphragmatic weakness, and colchicine 0...While neurologic involvement of Beh Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Mar 2023 | Trial primary completion date: Dec 2023 --> Mar 2023
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Preclinical, Journal:  Selective orexin 1 receptor antagonism does not affect effort-based responding for sucrose reward in rats. (Pubmed Central) -  Feb 8, 2024   
    In our experimental conditions neither SB-334867, nor two additional, structurally different SO1RAs, ACT-335827 and the clinical development candidate nivasorexant, affected effort-based responding for sucrose in rats. The positive control lisdexamfetamine, approved for psychiatric disorders associated with altered reward sensitivity such as binge eating disorder, increased effort-based responding.
  • ||||||||||  methylphenidate tablet / Generic mfg., lisdexamfetamine / Generic mfg.
    Evaluating if Stimulant Medication Use for Athletes with ADHD Levels the Playing Field on Baseline ImPACT (Shubert Complex (Posters 1-60) / Majestic Complex (Posters 61-120)) -  Dec 26, 2023 - Abstract #INSNewYork2024INS_Newyork_138;    
    Findings suggest that those diagnosed with ADHD and are using stimulants had significantly worse performance in impulse control at baseline when compared to those who do not have ADHD and denied medication use. This has implications for concussion monitoring for individuals who endorse having ADHD and are using stimulant medication.
  • ||||||||||  lisdexamfetamine / Generic mfg., azithromycin / Generic mfg.
    Journal:  Drug-Induced Hepatitis in an Adolescent During Concomitant Use of Azithromycin and Lisdexamfetamine Dimesylate. (Pubmed Central) -  Dec 22, 2023   
    Although hepatotoxicity has been reported with azithromycin and other macrolide antibiotics in adults, such a condition has yet to be reported in pediatrics. In light of this report, providers should be aware of a potentially rare reaction of acute hepatitis when combining azithromycin and lisdexamfetamine in pediatric patients.